Curaleaf Sets the Record Straight Against Aurora's Rejection of Offer

On October 19, 2026, Curaleaf Holdings, Inc. (TSX: CURA) issued a robust response to Aurora Cannabis Inc.'s warning against its enhanced proposal. Curaleaf, a leader in the cannabis product sector, feels strongly that Aurora's Board of Directors is neglecting its fiduciary responsibility to shareholders by dismissing Curaleaf's bid. CEO Boris Jordan did not hold back, asserting that the board's actions reflect neither logic nor a commitment to maximizing shareholder value.

The Situation Unfolds

In a recent communication, Aurora's Board again urged shareholders to reject Curaleaf's proposal. Curaleaf, however, highlights what it sees as a series of inconsistencies and unfounded claims made by Aurora. Jordan stated, “Aurora's Board has a fiduciary duty to its shareholders, which requires it not to take illogical steps to keep the highest bidder out of the room.” The stark contention arises from the fact that Curaleaf is the only entity offering a binding deal in favor of acquiring Aurora.

Curaleaf's management asserted that the board has been locking them out of crucial diligence access while simultaneously allowing other unnamed parties to explore confidential Aurora information. This stance led Curaleaf to express that Aurora's narrative simply does not hold when reviewed against the backdrop of real, verified facts.

Addressing Common Misconceptions

Curaleaf laid out several counterclaims to the narrative put forth by Aurora:

1. Claim: "Aurora's process is designed to deliver the best outcome for shareholders."
Fact: As reported, the board is reportedly favoring other potential bidders while sidelining Curaleaf, raising questions about their commitment to shareholder interests.

2. Claim: "The revised hostile bid is inadequate."
Fact: Curaleaf's revised proposal includes an 86% premium on Aurora's stock value as well as a staggering 217% when excluding cash assets from the equation. Curaleaf underscores that cash itself should not contribute to valuation premiums, pointing out discrepancies in Aurora's pricing history.

3. Claim: "Curaleaf's stocks are overvalued."
Fact: The implied transaction multiple derived from Aurora's adjusted earnings is exceeding Curaleaf's, contradicting Aurora’s claim regarding inflated valuations.

As Curaleaf builds its case, they assert that Aurora's leadership is enmeshed in a rhetoric that does not correlate with their financial reality. Reports from industry analysts confirm that a majority seem to agree with Curaleaf’s assessments regarding shareholder value.

The Way Forward

Curaleaf remains open to dialogue and eager to establish constructive discussions regarding diligence and potential synergies. The company emphasizes their readiness to provide detailed insights into how the acquisition could create extensive shareholder value. Their stance is bolstered by independent financial advisories, which are urging a reevaluation of Aurora's dismissal of Curaleaf’s proposal.

This ongoing battle exemplifies a critical moment in the corporate landscape for both companies, potentially altering the trajectory of cannabis industry mergers and acquisitions. As shareholders delve into the implications of the proposed offer, the call for transparency and factual engagement becomes not just relevant but paramount in guiding future decisions.

For more details on Curaleaf’s enhanced proposal and insights on this unfolding narrative, visit Curaleaf.

Investors and stakeholders are encouraged to consider the merits of Curaleaf’s engagement, as the outcome could very well shape the dynamics of the cannabis marketplace. The narrative continues to unfold, and with Curaleaf presenting new arguments and pleas for engagement, the next steps for Aurora’s board will be pivotal to watch.

Curaleaf remains steadfast in its mission to enhance lives through the power of the cannabis plant while adhering to principles of transparency and shareholder engagement.